RN341 is a LRRK2-specific type II kinase inhibitor (IC50 of 296 nM). It prevents the phosphorylation of LRRK2 by stabilizing an open conformation, thereby avoiding S935 dephosphorylation. Additionally, RN341 rescues LRRK2-mediated kinesin motility blockage by preventing microtubule binding. This compound effectively inhibits both wild-type and G2019S LRRK2 at the cellular level, offering a novel avenue for Parkinsons disease research.
Target-Kategorie:
LRRK2
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
